Related Experiment Video
Updated: Feb 4, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
Case Report: FIA plus venetoclax in a patient on hemodialysis
Jacob E Herstein1, Kayleigh R Marx2, J Michael Savoy2
1Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, United States.
Abstract:
The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Data Reporting and Recording
Hemodialysis III: Nursing Management
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:

